STOCK TITAN

T. Rowe Price holds 7.7% of Vera Therapeutics (VERA) common stock

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. reports beneficial ownership of 5,461,988 shares of Vera Therapeutics common stock, representing 7.7% of the class as of December 31, 2025. It has sole voting power over 5,376,319 shares and sole dispositive power over 5,461,976 shares, with no shared voting or dispositive power.

The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Associates, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:02/17/2026
Vera Therapeutics, Inc.

NASDAQ:VERA

VERA Rankings

VERA Latest News

VERA Latest SEC Filings

VERA Stock Data

3.00B
56.80M
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE